Limits...
Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China.

Li AQ, Zhou SL, Li M, Xu Y, Shui RH, Yu BH, Yang WT - PLoS ONE (2015)

Bottom Line: The prognostic significance of PR expression appeared more pronounced in patients under a high Ki-67 status than those under a low Ki-67 status.Based on these findings, we propose the use of a novel threshold of 20% to define PgR status.Nevertheless, the impact of this new criterion on patient management and clinical treatment requires additional study.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, P.R. China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.

ABSTRACT

Purpose: A lack of progesterone receptor (PgR) expression in oestrogen receptor-positive (ER+) tumours is associated with worse survival. PgR status is usually defined as positive or negative using 1% positive nuclei as a cut-off point. In this study, we aimed to assess the clinicopathologic characteristics of ER+/PgR-/HER2- tumours by comparing them with ER+/PgR+/HER2- tumours using a PgR cut-off point of 20% as a divisive criterion.

Methods: We analysed 1,522 patients with primary breast cancer who had undergone surgery at the Cancer Center of Fudan University between 2012 and 2014. Age, grade, tumour size, lymph node status and lymphovascular invasion were assessed. Multinomial logistic regression, linear regression and chi-square test models were applied to assess associations between ER, PR and clinical features.

Results: ER+/PgR-/HER2- tumours showed poorer clinicopathologic characteristics relative to ER+/PgR+/HER2- tumours using a PgR threshold of 20% instead of 1%. The clinicopathologic characteristics did not differ between tumours with purely negative PgR expression and tumours with a PgR percentage ranging from 1% to 19%. The prognostic significance of PR expression appeared more pronounced in patients under a high Ki-67 status than those under a low Ki-67 status.

Conclusions: Based on these findings, we propose the use of a novel threshold of 20% to define PgR status. Nevertheless, the impact of this new criterion on patient management and clinical treatment requires additional study.

No MeSH data available.


Related in: MedlinePlus

Distribution of ER expression as percentage of immunoreactive cells for the PgR-positive and PgR-negative groups.Histogram bars are in 10-unit bins, beginning with 1% of cells, 1% to 10%, 11% to 20%, etc. The ER+/PgR+/HER2- group consisted of 27 (2.3%) patients with ER <50% and 1129 (97.7%) patients with ER ≥50%. The ER+/PgR-/HER2- group consisted of 62 (16.9%) patients with ER <50% and 304 (83.1%) patients with ER ≥50%. The number of patients with a higher level of ER expression (ER ≥50%) in the ER+/PgR+/HER2- group was significantly larger that in the ER+/PgR-/HER2- group (P < 0.0001).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4418610&req=5

pone.0125067.g002: Distribution of ER expression as percentage of immunoreactive cells for the PgR-positive and PgR-negative groups.Histogram bars are in 10-unit bins, beginning with 1% of cells, 1% to 10%, 11% to 20%, etc. The ER+/PgR+/HER2- group consisted of 27 (2.3%) patients with ER <50% and 1129 (97.7%) patients with ER ≥50%. The ER+/PgR-/HER2- group consisted of 62 (16.9%) patients with ER <50% and 304 (83.1%) patients with ER ≥50%. The number of patients with a higher level of ER expression (ER ≥50%) in the ER+/PgR+/HER2- group was significantly larger that in the ER+/PgR-/HER2- group (P < 0.0001).

Mentions: In the ER+/PgR+/HER2- group, the ER percentage ranged from 10% to 100% (median, 88.5%), and the PgR percentage ranged from 20% to 100% (median, 69.1%); none of the tumours expressed ER in the range of 1% to 9%. In the ER+/PgR-/HER2- group, the ER percentage ranged from 1% to 100% (median, 71.8%), and the tumours of 22 patients expressed ER at levels <10%, whereas the PgR percentage ranged from 0% to 15% (median, 3.3%). The distributions of ER scores in two groups are displayed in Fig 2. Higher ER expression (ER ≥ 50%) was more common in the ER+/PgR+/HER2- group than the ER+/PgR-/HER2- group (P < 0.0001). An association between ER, PR expression and clinicopathologic variables was observed in ER+/PgR+/HER2- tumours (Fig 3). The expression levels of ER and PR were directly correlated with the favourability of the clinicopathologic characteristics in ER+/PgR+/HER2- tumours.


Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China.

Li AQ, Zhou SL, Li M, Xu Y, Shui RH, Yu BH, Yang WT - PLoS ONE (2015)

Distribution of ER expression as percentage of immunoreactive cells for the PgR-positive and PgR-negative groups.Histogram bars are in 10-unit bins, beginning with 1% of cells, 1% to 10%, 11% to 20%, etc. The ER+/PgR+/HER2- group consisted of 27 (2.3%) patients with ER <50% and 1129 (97.7%) patients with ER ≥50%. The ER+/PgR-/HER2- group consisted of 62 (16.9%) patients with ER <50% and 304 (83.1%) patients with ER ≥50%. The number of patients with a higher level of ER expression (ER ≥50%) in the ER+/PgR+/HER2- group was significantly larger that in the ER+/PgR-/HER2- group (P < 0.0001).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4418610&req=5

pone.0125067.g002: Distribution of ER expression as percentage of immunoreactive cells for the PgR-positive and PgR-negative groups.Histogram bars are in 10-unit bins, beginning with 1% of cells, 1% to 10%, 11% to 20%, etc. The ER+/PgR+/HER2- group consisted of 27 (2.3%) patients with ER <50% and 1129 (97.7%) patients with ER ≥50%. The ER+/PgR-/HER2- group consisted of 62 (16.9%) patients with ER <50% and 304 (83.1%) patients with ER ≥50%. The number of patients with a higher level of ER expression (ER ≥50%) in the ER+/PgR+/HER2- group was significantly larger that in the ER+/PgR-/HER2- group (P < 0.0001).
Mentions: In the ER+/PgR+/HER2- group, the ER percentage ranged from 10% to 100% (median, 88.5%), and the PgR percentage ranged from 20% to 100% (median, 69.1%); none of the tumours expressed ER in the range of 1% to 9%. In the ER+/PgR-/HER2- group, the ER percentage ranged from 1% to 100% (median, 71.8%), and the tumours of 22 patients expressed ER at levels <10%, whereas the PgR percentage ranged from 0% to 15% (median, 3.3%). The distributions of ER scores in two groups are displayed in Fig 2. Higher ER expression (ER ≥ 50%) was more common in the ER+/PgR+/HER2- group than the ER+/PgR-/HER2- group (P < 0.0001). An association between ER, PR expression and clinicopathologic variables was observed in ER+/PgR+/HER2- tumours (Fig 3). The expression levels of ER and PR were directly correlated with the favourability of the clinicopathologic characteristics in ER+/PgR+/HER2- tumours.

Bottom Line: The prognostic significance of PR expression appeared more pronounced in patients under a high Ki-67 status than those under a low Ki-67 status.Based on these findings, we propose the use of a novel threshold of 20% to define PgR status.Nevertheless, the impact of this new criterion on patient management and clinical treatment requires additional study.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, P.R. China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.

ABSTRACT

Purpose: A lack of progesterone receptor (PgR) expression in oestrogen receptor-positive (ER+) tumours is associated with worse survival. PgR status is usually defined as positive or negative using 1% positive nuclei as a cut-off point. In this study, we aimed to assess the clinicopathologic characteristics of ER+/PgR-/HER2- tumours by comparing them with ER+/PgR+/HER2- tumours using a PgR cut-off point of 20% as a divisive criterion.

Methods: We analysed 1,522 patients with primary breast cancer who had undergone surgery at the Cancer Center of Fudan University between 2012 and 2014. Age, grade, tumour size, lymph node status and lymphovascular invasion were assessed. Multinomial logistic regression, linear regression and chi-square test models were applied to assess associations between ER, PR and clinical features.

Results: ER+/PgR-/HER2- tumours showed poorer clinicopathologic characteristics relative to ER+/PgR+/HER2- tumours using a PgR threshold of 20% instead of 1%. The clinicopathologic characteristics did not differ between tumours with purely negative PgR expression and tumours with a PgR percentage ranging from 1% to 19%. The prognostic significance of PR expression appeared more pronounced in patients under a high Ki-67 status than those under a low Ki-67 status.

Conclusions: Based on these findings, we propose the use of a novel threshold of 20% to define PgR status. Nevertheless, the impact of this new criterion on patient management and clinical treatment requires additional study.

No MeSH data available.


Related in: MedlinePlus